Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

A Pilot Study to Assess the Preliminary Efficacy of EDTA Eye Drops on Band Keratopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03985371
Recruitment Status : Not yet recruiting
First Posted : June 13, 2019
Last Update Posted : January 29, 2020
Livionex Inc
Information provided by (Responsible Party):
James V. Aquavella, MD, University of Rochester

Brief Summary:
The objective of this study is to collect preliminary efficacy and safety data on the use of EDTA EYE Drops (EED) on subjects during an episode of band keratopathy (BK).

Condition or disease Intervention/treatment Phase
Corneal Dystrophy, Band-Shaped Drug: EDTA Eye Drops Early Phase 1

Detailed Description:

This study is an open-label, pilot study of up to 6 subjects with documented BK.

This study has 2 phases: In Phase 1 subjects must be willing to return to the clinic for evaluation of safety and BK symptoms during the treatment period of 6 months (Days 7, 60, 120, 180) and for follow up at Months 9 and 12. In Phase 2 subjects must be willing to return to the clinic at 18 and 24 months post-first dose for a final evaluation.

On Day 1 of the study, potential subjects will be screened and if they meet entry requirements they will be enrolled in the study.

Once enrolled, subjects will be assessed for baseline symptoms and visual acuity, have corneal photographs taken of their affected eye, dispensed EED and instructed to use it for 2 times/day for 6 months in the eye with BK. They will be dosed for the first time in the clinic in order to show them how to consistently use the drops. Subjects will also be given a diary card to record potential adverse events and pain levels (with the first level being noted in the clinic), dismissed from the clinic and reminded to return on Day 7 for assessment of tolerability and safety.

At each subsequent visit (Days 7, 60, 120, 180) the subject will be asked to rate their pain at the time of the visit on a pain analog scale. Their diary card will be reviewed for potential adverse events (AEs) and use of EED will be assessed for technique and compliance. Between visits, subjects will be called every 4 weeks by a member of the study site team to assess potential AEs and dosing compliance.

Additionally, the subject or their caregiver will check the treated eye on a weekly basis and note whether the calcific bands are still present on the diary card. When bands have disappeared, subject will notify the eye clinic and schedule a return visit to obtain corneal photographs and visual acuity test. This may occur outside the planned study visits.

On Day 180, subjects will present at the clinic to return their diary card and unused study product. They will be asked to return to the clinic on Days 270 and 360 for assessment of their visual acuity, pain, corneal photography of the affected eye and potential AEs.

Day 360 will be considered the end of study phase 1. Phase 2 of the study includes long term follow up for possible recurrence. Subjects will be scheduled to return for follow-up visits at months 18 and 24 for assessment of visual acuity and recurrence of BK symptoms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Pilot Study to Assess the Safety, Tolerability and Preliminary Efficacy of EDTA Eye Drops on Band Keratopathy
Estimated Study Start Date : February 2020
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2021

Arm Intervention/treatment
Experimental: Drops Used Drug: EDTA Eye Drops
One drop in the Band Keratopathy affected eye only, two times per day for six months.

Primary Outcome Measures :
  1. Changes of the Cornea [ Time Frame: Days 1, 120 and 180 after the start of the study. ]
    Photographs will be full, direct views taken with a Zeiss model 450 plus split lamp camera.

  2. Change in Snellen Visual Acuity [ Time Frame: Days 1, 7, 60, 120 and 180 after the start of the study. ]
    The Snellen Chart is used to assess visual acuity by asking subjects to read as many of the 11 lines of block letters as they are able.

  3. Change in the Symptoms Associated with Band Keratopathy [ Time Frame: Days 1, 7, 60, 180, 270, 360, 540 and 720 after the start of the study. ]
    Evaluation of pain, as rated by the subject on a visual analog scale, will be the primary symptom assessed throughout this study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Understand the requirements of the study and provide informed consent prior to undergoing any study-related procedures
  2. Be between the ages of 40 and 80 years old, inclusive
  3. Have a documented BK diagnosis
  4. Be willing and able to comply with protocol-specified dosing, visits to the clinic and tracking of symptoms

Exclusion Criteria:

  1. Use other therapies for BK including amniotic membrane or conjunctival grafts.
  2. Have other co-morbidities that may confound the safety and efficacy measurements for this study.
  3. Have participated in any other clinical trial within 30 days prior to enrollment.
  4. Have any condition, abnormality or situation at Baseline that in the opinion of the Principal Investigator may preclude the subject's ability to comply with study requirements, including completion of the study

Layout table for additonal information
Responsible Party: James V. Aquavella, MD, Professor, University of Rochester Identifier: NCT03985371    
Other Study ID Numbers: 3712
First Posted: June 13, 2019    Key Record Dates
Last Update Posted: January 29, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by James V. Aquavella, MD, University of Rochester:
Band Keratopathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Ophthalmic Solutions
Pharmaceutical Solutions